Gist clinical trials

Explore recruiting gist clinical trials.

Recruiting gist studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Gist trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Three versus five years of adjuvant imatinib as treatment of patients with operable GIST with a high risk for recurrence: A randomised phase III study.

Sweden, Finland, Norway, Germany, Austria, Netherlands +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A FIRST-IN-HUMAN (FIH) STUDY OF IDRX-42 IN PARTICIPANTS WITH METASTATIC AND/OR UNRESECTABLE GASTROINTESTINAL STROMAL TUMORS (GIST)

France, Spain, Netherlands, Germany, Belgium, Italy

Phase I and Phase II (Integrated)- Other EU CTIS Study details

GIST-TEN: Randomized, prospective, multicentre, open label phase II study evaluating the interest of imatinib (Glivec) treatment maintenance or interruption after at least 10 years of treatment in patients with locally advanced/metastatic Gastrointestinal Stromal Tumors (GISTs)

France

Therapeutic exploratory (Phase II) EU CTIS Study details

(Peak) A Phase 3 Randomized, Open-label, Multicenter Clinical Study of CGT9486+Sunitinib vs Sunitinib in Subjects with Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors

Germany, Spain, Sweden, Denmark, Hungary, France +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Master Protocol for the Multi-Cohort, Phase 1/2 Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies

Portugal, Netherlands, Denmark, Spain, Italy, Germany +2 more

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 1/2 Study of the Safety, Pharmacokinetics and Anti-Tumor Activity of the Oral KIT Inhibitor THE-630 in Patients with Advanced Gastrointestinal Stromal Tumors (GIST)

Spain, France

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Gist trials by city

Gist in Toronto Gist in Vancouver Gist in Montreal Gist in Calgary Gist in Edmonton Gist in Ottawa Gist in Winnipeg Gist in Quebec City Gist in Hamilton Gist in Kitchener Gist in London Gist in Halifax Gist in New York Gist in Los Angeles Gist in Chicago Gist in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease